CliffBio
small molecule

BUSULFAN

BUSULFAN

Loss of exclusivity—loss of exclusivity
CompanyNexus Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameBUSULFAN
Active ingredientBUSULFAN
Strength6MG/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJanuary 2019
Marketing statusDISCN

More from Nexus Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BUSULFAN patent cliff — loss of exclusivity — | CliffBio